Why dose escalation exists
GLP-1 receptor agonists produce nausea, bloating, and sometimes vomiting when exposure increases too quickly. The escalation schedule is the pharmaceutical solution: start low enough that the GI tract adapts, then advance in increments spaced wide enough to allow that adaptation before the next step.
Skipping or compressing steps doesn’t unlock faster results; it overwhelmingly increases the likelihood of side effects severe enough to cause patients to discontinue. The schedule exists for the patient’s benefit, not as bureaucratic caution.
Semaglutide dose escalation: standard structure
The semaglutide dosing chart used in large clinical trials (STEP program) and reflected in branded prescribing information follows this general escalation:
| Week range | Weekly dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | Initiation / GI acclimation |
| Weeks 5–8 | 0.5 mg | First therapeutic level |
| Weeks 9–12 | 1 mg | Standard maintenance level |
| Week 13+ | 2 mg (optional) | If clinician-directed for additional response |
Compounded semaglutide programs prescribed through licensed telehealth clinicians generally follow the same escalation logic, adjusted for the individual patient. Compounded semaglutide is not an FDA-approved drug; it is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.
Tirzepatide dose escalation: standard structure
Tirzepatide is a dual GIP/GLP-1 receptor agonist, which means it activates two incretin pathways simultaneously. Its escalation schedule is longer and uses more increments, reflecting both its potency and the need for careful GI adaptation:
| Week range | Weekly dose | Step |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Initiation |
| Weeks 5–8 | 5 mg | Step 2 |
| Weeks 9–12 | 7.5 mg | Step 3 |
| Weeks 13–16 | 10 mg | Step 4 |
| Weeks 17–20 | 12.5 mg | Step 5 |
| Week 21+ | 15 mg (max) | Maximum approved dose |
As with semaglutide, many patients find an effective maintenance dose before reaching the maximum. Not everyone escalates all the way to 15 mg; the goal is the lowest effective dose, not the highest tolerated one.
A dosing chart is a map of the road, not a driver — the milligrams come from the trials, the pace comes from your clinician.
What does a GLP-1 dosing chart NOT account for?
A GLP-1 dosing chart shows the structural scaffold of a protocol. It does not account for:
- Kidney function: Reduced renal clearance changes how GLP-1 drugs behave at steady state and may warrant slower escalation or dose caps.
- GI history: A history of gastroparesis, inflammatory bowel disease, or prior GI surgery significantly alters tolerability and may contraindicate GLP-1 use entirely.
- Concomitant medications: Oral medications whose absorption depends on gastric emptying rate can be affected by GLP-1-mediated slowing of digestion. This requires medication review, not a chart.
- Personal metabolic response: Some patients achieve excellent weight-management support at 0.5 mg semaglutide weekly; others need 2 mg. There is no universal dose.
- Thyroid history: GLP-1 receptor agonists carry a boxed warning regarding a potential risk of thyroid C-cell tumors in rodent studies (clinical significance in humans is unresolved). A personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication. A chart does not screen for this.
Managing side effects during escalation
GI side effects, primarily nausea and sometimes vomiting or diarrhea, are most common in the first one to two weeks after each dose increase. The clinical strategies that reduce them:
- Eat smaller portions and avoid high-fat, high-calorie meals immediately after injection
- Inject at night so peak side-effect window occurs during sleep
- Stay well hydrated
- Hold at the current dose for longer than four weeks if side effects are not fully resolved
- Contact your clinician before reducing or stopping, as structured tapering guidance applies
None of these substitutes for clinician guidance. If nausea is persistent across multiple weeks or accompanied by severe vomiting and inability to keep fluids down, that is a clinical conversation, not a “wait it out” situation.
Does compounded GLP-1 follow the same dosing chart as the branded drug?
Patients sometimes ask whether compounded semaglutide or tirzepatide follows a different dosing chart than the branded version. The escalation structure is the same: the milligram amounts and the four-week minimum per step derive from the clinical trial data, not from the brand. What differs is the supply chain.
Compounded GLP-1 medications prescribed through PepScribe are prepared by licensed 503A compounding pharmacies in the United States. Compounded products are not FDA-approved and are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. They are not manufactured by the branded drug’s maker. The 503A standard means every preparation is patient-specific, clinician-ordered, and sourced domestically. No hidden overseas supply chain.
Frequently asked questions
What is the standard GLP-1 dosing chart for semaglutide?
Semaglutide dose escalation typically starts at 0.25 mg weekly for the first four weeks, advances to 0.5 mg, then 1 mg, and optionally 2 mg, with each step held for at least four weeks. The goal is the lowest dose that achieves the patient's weight-management targets while minimizing GI side effects. Clinicians individualize this schedule.
How does tirzepatide dose escalation compare to semaglutide?
Tirzepatide (a dual GLP-1/GIP agonist) typically starts at 2.5 mg weekly for four weeks, then advances in 2.5 mg increments through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg, again with each increment held for at least four weeks. Titration pace is clinician-directed.
Can I skip dose escalation steps if I feel fine?
Dose escalation exists to reduce nausea, vomiting, and other GI side effects, not just for safety optics. Skipping steps increases the risk of those effects significantly. Your prescribing clinician decides the titration pace based on your response.
Are compounded semaglutide and tirzepatide the same as Ozempic or Mounjaro?
Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are compounded in the USA by licensed 503A pharmacies and are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. The active ingredient may be the same molecule, but compounded products are not manufactured under the same conditions as branded products and carry different regulatory status.
What happens if GLP-1 side effects are too strong at my current dose?
The standard approach is to hold the current dose longer, or temporarily step back down, until side effects resolve. Never self-adjust a compounded GLP-1 without guidance from your prescribing clinician.
Is a GLP-1 dosing chart a substitute for a clinician?
No. A dosing chart conveys the general structure of approved escalation protocols; it cannot replace an individualized clinical assessment that accounts for your weight, kidney function, GI history, other medications, and treatment goals.